FT-003

FT-003 is a recombinant adeno-associated virus (rAAV) gene therapy developed by Frontera Therapeutics for the treatment of retinal diseases, specifically neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR)[1][2][4][8]. FT-003 is delivered by intravitreal injection and utilizes an optimized rAAV vector to express a humanized recombinant fusion protein homologous to aflibercept, which acts by inhibiting vascular endothelial growth factor (VEGF) activity, thereby reducing vascular proliferation and permeability in retinal tissues[8]. The therapy is designed to offer long-term, durable efficacy with a single injection, aiming to significantly reduce or eliminate the need for frequent anti-VEGF rescue injections traditionally required for these chronic diseases[1][2][4][8]. In clinical trials, FT-003 has shown significant improvements in visual acuity and retinal structure with a strong safety and tolerability profile[1][2][8].

Brand names

FT-003FT003FT 003

Other names

FT-003 InjectionFT003 InjectionFT 003 Injection